Insulin-like growth factor-1 attenuates cisplatin-induced γH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer

Cancer Letters

Volumn 272, Issue 2, 2008, Pages 232-241

  Jeon, Jeong Hee ^a   Kim, Se Kyu ^a,b   Kim, Hyung Jung ^a,b   Chang, Joon ^a,b   Ahn, Chul Min ^a,b   Chang, Yoon Soo ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

H2AX; Ataxia telangiectasia mutated; ATM Rad3 related; Cisplatin; Damaged DNA checkpoint; DNA DSBs repair system; DNA dependent protein kinase; Insulin like growth factor 1; Non small cell lung cancer

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CISPLATIN; DOUBLE STRANDED DNA; GAMMA HISTONE H2AX; HISTONE H2AX; INSULIN RECEPTOR SUBSTRATE 1; PROTEIN P53; SERINE; SOMATOMEDIN C; THREONINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFECT; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; COMET ASSAY; DNA DAMAGE; DNA REPAIR; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; RNA, SMALL INTERFERING;

ATAXIA TELANGIECTASIA;

EID: 55949097005     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.011     Document Type: Article

References (35)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J. Clin. 57 (2007) 43-66
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 (2005) 74-108
3. Bolliger C.T. Evaluation of operability before lung resection. Curr. Opin. Pulm. Med. 9 (2003) 321-326
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
5. Albain K.S., Rusch V.W., Crowley J.J., Rice T.W., Turrisi III A.T., Weick J.K., Lonchyna V.A., Presant C.A., McKenna R.J., Gandara D.R., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J. Clin. Oncol. 13 (1995) 1880-1892
6. Crul M., van Waardenburg R.C., Bocxe S., van Eijndhoven M.A., Pluim D., Beijnen J.H., and Schellens J.H. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem. Pharmacol. 65 (2003) 275-282
7. Fichtinger-Schepman A.M., van der Veer J.L., den Hartog J.H., Lohman P.H., and Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24 (1985) 707-713
8. Boeckman H.J., Trego K.S., and Turchi J.J. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol. Cancer Res. 3 (2005) 277-285
9. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
10. Petrini J.H., and Stracker T.H. The cellular response to DNA double-strand breaks: defining the sensors and mediators. Trends Cell Biol. 13 (2003) 458-462
11. Reinhardt H.C., Aslanian A.S., Lees J.A., and Yaffe M.B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11 (2007) 175-189
12. Benito M., Valverde A.M., and Lorenzo M. IGF-I: a mitogen also involved in differentiation processes in mammalian cells. Int. J. Biochem. Cell Biol. 28 (1996) 499-510
13. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., and Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst. 91 (1999) 151-156
14. Yang S., Chintapalli J., Sodagum L., Baskin S., Malhotra A., Reiss K., and Meggs L.G. Activated IGF-1R inhibits hyperglycemia-induced DNA damage and promotes DNA repair by homologous recombination. Am. J. Physiol. Renal Physiol. 289 (2005) F1144-F1152
15. Trojanek J., Ho T., Del Valle L., Nowicki M., Wang J.Y., Lassak A., Peruzzi F., Khalili K., Skorski T., and Reiss K. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol. Cell. Biol. 23 (2003) 7510-7524
16. Burma S., Chen B.P., Murphy M., Kurimasa A., and Chen D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 276 (2001) 42462-42467
17. Paull T.T., Rogakou E.P., Yamazaki V., Kirchgessner C.U., Gellert M., and Bonner W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol. 10 (2000) 886-895
18. Garber K. New checkpoint blockers begin human trials. J. Natl. Cancer Inst. 97 (2005) 1026-1028
19. Garber K. IGF-1: old growth factor shines as new drug target. J. Natl. Cancer Inst. 97 (2005) 790-792
20. Dimanche-Boitrel M.T., Meurette O., Rebillard A., and Lacour S. Role of early plasma membrane events in chemotherapy-induced cell death. Drug Resist. Updat. 8 (2005) 5-14
21. Párrizas M., Gazit A., Levitzki A., Wertheimer E., and LeRoith D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138 (1997) 1427-1433
22. Filipits M., Pirker R., Dunant A., Lantuejoul S., Schmid K., Huynh A., Haddad V., Andre F., Stahel R., Pignon J.P., Soria J.C., Popper H.H., Le Chevalier T., and Brambilla E. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J. Clin. Oncol. 25 (2007) 2735-2740
23. Wang G., Reed E., and Li Q.Q. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol. Rep. 12 (2004) 955-965
24. Fuertesa M.A., Castillab J., Alonsoa C., and Perez J.M. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr. Med. Chem. 10 (2003) 257-266
25. Kao J., Milano M.T., Javaheri A., Garofalo M.C., Chmura S.J., Weichselbaum R.R., and Kron S.J. Gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr. Cancer Drug Targets 6 (2006) 197-205
26. Rebillard A., Tekpli X., Meurette O., Sergent O., LeMoigne-Muller G., Vernhet L., Gorria M., Chevanne M., Christmann M., Kaina B., Counillon L., Gulbins E., Lagadic-Gossmann D., and Dimanche-Boitrel M.T. Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res. 67 (2007) 7865-7874
27. Ugi S., Imamura T., Ricketts W., and Olefsky J.M. Protein phosphatase 2A forms a molecular complex with Shc and regulates Shc tyrosine phosphorylation and downstream mitogenic signaling. Mol. Cell. Biol. 22 (2002) 2375-2387
28. Kiely P.A., O'Gorman D., Luong K., Ron D., and O'Connor R. Insulin-like growth factor I controls a mutually exclusive association of RACK1 with protein phosphatase 2A and beta1 integrin to promote cell migration. Mol. Cell. Biol. 26 (2006) 4041-4051
29. Adam R.M., Mukhopadhyay N.K., Kim J., Di Vizio D., Cinar B., Boucher K., Solomon K.R., and Freeman M.R. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res. 67 (2007) 6238-6246
30. Zhou B.B., and Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 408 (2000) 433-439
31. Berkovich E., Monnat Jr. R.J., and Kastan M.B. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat. Cell Biol. 9 (2007) 683-690
32. Gual P., Le Marchand-Brustel Y., and Tanti J.F. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87 (2005) 99-109
33. Delafontaine P., Song Y.H., and Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 435-444
34. Wu A., Chen J., and Baserga R. Nuclear insulin receptor substrate-1 activates promoters of cell cycle progression genes. Oncogene 27 (2008) 397-403
35. Trojanek J., Ho T., Croul S., Wang J.Y., Chintapalli J., Koptyra M., Giordano A., Khalili K., and Reiss K. IRS-1-Rad51 nuclear interaction sensitizes JCV T-antigen positive medulloblastoma cells to genotoxic treatment. Int. J. Cancer 119 (2006) 539-548